In Belgium, cartridges have been temporarily unavailable since April 1 and these supply problems should continue until December 31. “This is not a problem for patients because another treatment is possible and available,” said the Federal Agency for Medicines and Health Products (AFMPS). It may be a drug with another active substance, another pharmaceutical form, another path of administration or another dosage.
In order to reserve stocks for patients already treated, Novo Nordisk asked the prescribers not to start new treatments with FIASP or Novorapid Pumpcart until the end of the difficulties of supplying cartridges.
All the Member States where the product is marketed are currently affected or may be affected by the intermittent shortages of FIASP Pumpcart and Novorapid, the European Medicines Agency said in May. She had then quoted Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Luxembourg, the Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain and Sweden.
